Yes. First of all an mOS is not a good indicator at all in expressing the efficacy of immunotherapy drugs. The world is used to capture the median values in an abstract of an R&D article and the same dame approach is no good in immunotherapy papers in my humble opinion. The abstract should rather list one yr, 2 yr, 3 yr %of patients alive in treatment vs placebo or standard therapy ..... that should be the norm hereafter so that the fudsters like Ex can be stopped in their attempt to confuse the commons.
The thin black line is for the interim blended data as presented in 2018. If you removed the control patients from the interim blended data, you get the final DCVax-L data from the JAMA article.
Graph courtesy of Jammy James who was a contributor here.
Market Data 
Markets 
AI
